[BrightGene Biotech] Announcement of Board of Directors' Approval of First Quarter 2026 Consolidated Financial Report
NQ Score
0/100
N1 Content Completeness
0.9
AI Summary (NQ-processed)
BrightGene Biotech's Board of Directors approved the consolidated financial report for the first quarter of 2026 (115 ROC year). The company reported operating revenue of NT$84.385 million, profit before tax of NT$27.985 million, net profit of NT$23.944 million, and basic EPS of NT$0.97.